donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > GSK GlaxoSmithKline > Key Indicators
GSK GlaxoSmithKline
43.350
-0.350-0.80%
Pre Mkt Price
43.240
-0.11-0.25%
YOY
Do not show
Hide blank lines
(Q1)2022/03/31(FY)2021/12/31(Q4)2021/12/31(Q3)2021/09/30
Financial Ratios
Efficiency Ratios TTM
Cash Conversion Cycle(D)
-0.01% -210.4025 -3.75% 108.5086 -3.75% 108.5086 -19.14% -205.813
Receivable Turnover(T)
14.24% 4.9319 -6.39% 5.7845 -6.39% 5.7845 0.25% 4.286
Inventory Turnover(T)
16.15% 2.0972 0.52% 1.9701 0.52% 1.9701 -1.88% 1.7493
Fixed Assets Turnover(T)
16.17% 3.419 3.01% 3.1473 3.01% 3.1473 1.87% 3.0474
Total Asset Rate(T)
8.93% 0.4348 0.41% 0.4277 0.41% 0.4277 0.05% 0.4176
ROIC
-7.82% 12.838% -19.22% 12.568% -19.22% 12.568% -26.33% 12.008%
ROE
-12.39% 32.945% -33.12% 29.586% -33.12% 29.586% -40.63% 29.032%
ROA
-5.8% 6.097% -23.44% 5.497% -23.44% 5.497% -30.37% 5.404%
FCF to Sales
11.72% 19.150% -19.08% 14.718% -19.08% 14.718% -14.4% 14.691%
FCF to Net Income
29.19% 136.586% 6.14% 114.504% 6.14% 114.504% 23% 113.517%
Efficiency Ratios
ROE 5 Year Average
-- -- 0.06% 118.346% -- -- -- --
ROA 5 Year Average
-- -- 15.8% 5.681% -- -- -- --
Average 5 Years ROIC
-- -- 8.66% 14.319% -- -- -- --
Profitability Ratios TTM
Gross Margin
-1.89% 64.873% 0.47% 65.988% 0.47% 65.988% 1.67% 66.711%
Operating Margin
17.33% 21.359% 7.33% 19.590% 7.33% 19.590% -37.87% 14.427%
Net Margin
-13.52% 14.020% -23.76% 12.854% -23.76% 12.854% -30.41% 12.942%
EBITDA Margin
-10.81% 0.275% -15.56% 0.252% -15.56% 0.252% 30.66% 0.3314%
R & D Expense Ratio
-5.87% 14.600% 3.48% 15.470% 3.48% 15.470% 11.81% 15.900%
Sales Expense Ratio
-- 0.000% -- 0.000% -- 0.000% -- 0.000%
Administration Expense Rate
-7.66% 31.230% -4.26% 32.170% -4.26% 32.170% -4.73% 32.640%
Financial Health Ratios
Long-Term Debt to Equity Ratio
16.5% 180.619% -14.91% 136.646% -14.91% 136.646% -17.7% 134.422%
Total Assets to Common Equity
5.53% 554.286% -4.71% 525.427% -4.71% 525.427% -9.95% 510.106%
Debt to Asset Ratio
16.78% 205.970% -13.73% 160.565% -13.73% 160.565% -16.06% 165.986%
Current Ratio
30.69% 1.194 -13.7% 0.7889 -13.7% 0.7889 -9.16% 0.8143
Quick Ratio
64.51% 0.9176 -14.37% 0.4935 -14.37% 0.4935 -9.23% 0.5001
GrowthRatios
Growth Ratios
Revenue CAGR(3Y)
-- -- -17% 3.442% -- -- -- --
Revenue CAGR(5Y)
-- -- -44.03% 4.112% -- -- -- --
Net Income CAGR(3Y)
-- -- -88.14% 6.570% -- -- -- --
Net Income CAGR(5Y)
-- -- 601.86% 36.897% -- -- -- --
Dividend CAGR(3Y)
-- -- 38.02% -0.409% -- -- -- --
Dividend CAGR(5Y)
-- -- 369.04% 0.539% -- -- -- --
FCF 1 Year Growth
-- -- -423.28% -19.042% -- -- -- --
FCF CAGR(3Y)
-- -- -192.33% -8.827% -- -- -- --
FCF CAGR(5Y)
-- -- -93.04% 3.909% -- -- -- --
Currency Unit
GBPGBPGBPGBP

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Merck KGaA; Lyell Immunopharma; CEPI; Innovax and Xiamen University; VBI; and Viome. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
CEO: Walmsley, Emma N.
Market: NYSE
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...